Immunization - Vaccine Updates
(Last updated 09/10/2015)
CDC publishes 2015–16 influenza vaccination recommendations in MMWR
CDC published Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season in the August 7 issue of MMWR (pages 818–825). The first paragraph is reprinted below.
This report updates the 2014 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines. Updated information for the 2015–16 season includes 1) antigenic composition of U.S. seasonal influenza vaccines; 2) information on influenza vaccine products expected to be available for the 2015–16 season; 3) an updated algorithm for determining the appropriate number of doses for children aged 6 months through 8 years; and 4) recommendations for the use of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) when either is available, including removal of the 2014–15 preferential recommendation for LAIV for healthy children aged 2 through 8 years. Information regarding topics related to influenza vaccination that are not addressed in this report is available in the 2013 ACIP seasonal influenza recommendations.
The complete article with 2015-16 influenza vaccination recommendations can be found at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm.
New Influenza Vaccine Information Statements Now Available
On August 7, 2015 CDC issued two new Influenza Vaccine Information Statements (VISs). The VIS for Influenza (Flu) Vaccine (Inactivated or Recombinant) is intended for use with all non-live virus formulations—trivalent, quadrivalent, cell-culture, recombinant, intradermal, and high-dose. The VIS for Influenza (Flu) Vaccine (Live, Intranasal) is intended for use when administering nasal-spray vaccine.
Important Note: The flu season dates (i.e., 2015-16) are not listed at the top of these VISs. These VISs may be used for this and future years, until there is a significant change in flu recommendations that will require changing them.
IAC's screening checklists for vaccines have been updated
Immunization Action Coalition (IAC) recently updated the following checklists for vaccine contraindications.
- Screening Checklist for Contraindications to Inactivated Injectable Influenza Vaccination
- Screening Checklist for Contraindications to Live Attenuated Intranasal Influenza Vaccination
- Screening Checklist for Contraindications to Vaccines for Adults
- Screening Checklist for Contraindications to Vaccines for Children and Teens
Seasonal Influenza Vaccination Resources for Health Professionals
The most current information for health care professionals regarding influenza vaccine recommendations (including persons with egg allergy), vaccine supply, and recommendations for using antiviral agents for influenza can be found on the CDC website at www.cdc.gov/flu/professionals/vaccination/index/htm.
CDC publishes updated ACIP recommendations regarding the intervals between PCV13 and PPSV23 vaccines for use in immunocompetent adults age 65 years and older
In the September 4 issue of MMWR (pages 944–947), CDC published Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
On June 25, 2015, ACIP changed the recommended interval between PCV13 followed by PPSV23 (PCV13–PPSV23 sequence) from 6–12 months to ≥1 year for immunocompetent adults aged ≥65 years. Recommended intervals for all other age and risk groups remain unchanged. The report outlines the rationale for this change and summarizes the evidence considered by ACIP to make this recommendation. The "Summary" section is reprinted below in its entirety.
Summary: What is currently recommended?
The Advisory Committee on Immunization Practices (ACIP) currently recommends that both 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) be given to all immunocompetent adults aged ≥65 years. ACIP recommends that PCV13 be given first followed by PPSV23 6–12 months later. ACIP also recommends that adults aged ≥65 years who already received a dose of PPSV23, should also receive a dose of PCV13 ≥1 year after the dose of PPSV23. Among persons aged ≥2 years with medical indications to receive both PCV13 and PPSV23 in a series, including adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, cochlear implants, or cerebrospinal fluid leaks, a dose of PPSV23 should be given ≥8 weeks after a dose of PCV13.
Why are the recommendations being modified now?
To simplify the recommendations for PCV13 and PPSV23 use among immunocompetent adults aged ≥65 years, ACIP recommended harmonization of recommended intervals between PCV13 and PPSV23 regardless of the order in which the two vaccines are given.
What are the new recommendations?
ACIP recommends that both PCV13 and PPSV23 be given in series to adults aged ≥65 years. A dose of PCV13 should be given first followed by a dose of PPSV23 at least 1 year later to immunocompetent adults aged ≥65 years. The two vaccines should not be co-administered. If a dose of PPSV23 is inadvertently given earlier than the recommended interval, the dose need not be repeated.
Read the full-text article to access the complete recommendations; a PDF version of the entire issue is also available.
CDC updates its Vaccine Storage & Handling Toolkit
In May 2014, CDC released an updated version of its Vaccine Storage & Handling Toolkit, originally published online in 2012. The toolkit is based on the recommendations of the Advisory Committee on Immunization Practices (ACIP), equipment manufacturers' product information, and studies from the National Institute for Scientific Technology. Here's a direct link to the updated PDF document.
The toolkit outlines best practice strategies and recommendations on the following topics:
- Equipment considerations for storage units and temperature monitoring devices
- Maintaining the cold chain
- Routine storage and handling practices
- Inventory management
- Emergency procedures for protecting vaccine inventories
On the toolkit web page, you'll also find related resources such as training materials, slide sets, and other helpful items.
Draft Immunization Protocols
OPA annually drafts immunization protocols in compliance with the Ohio State Board of Pharmacy’s rules. Updated protocols for 2015 are now available. Use the following link to purchase the protocol package: TCSLINKTOFORM[15,Immunization Protocol Package form]
HealthMap Vaccine Finder
HealthMap Vaccine Finder (http://flushot.healthmap.org) is a free, online service where users can search for locations offering flu vaccines, as well as other adult vaccines. This service partners with clinics, pharmacies, and health departments to provide accurate and up-to-date information about receiving the flu vaccine.
In 2012, Google passed the baton to HealthMap when it retired Google Flu Vaccine Finder. If you previously provided data to Google Flu Vaccine Finder and would like to still be included in the list of vaccine providers, you will need to register and upload your location data to HealthMap.